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19-Nortestosterone C-17 epimers with prominent antiproliferative properties have been
previously described. In our present study, five novel 17α-19-nortestosterones (3–7)
were synthesized to increase their beneficial biological activities with no associated
undesired hormonal effects. The compounds were screened by a viability assay
against a panel of human adherent gynecological cancer cell lines. Three of the
tested derivatives (3–5) exhibited a remarkable inhibitory effect on the proliferation of
HeLa cells with IC50 values lower than that of our reference agent cisplatin (CIS).
These three active agents also displayed considerable cancer selectivity as evidenced
by their weaker growth inhibitory effect on non-cancerous fibroblast cells compared
to CIS. The most potent newly synthesized 17α-chloro derivative (3) was selected
for additional experiments in order to characterize its mechanism of action. Since
nandrolone (19-nortestosterone, 1) is a structural analog with selective antiproliferative
action on cervical carcinoma cells, it was utilized as a positive control in these studies.
A lactate dehydrogenase (LDH) assay demonstrated a moderate cytotoxic effect of the
test compounds. Cell cycle disturbance and the elevation of the hypodiploid population
elicited by the test agents were detected by flow cytometry following propidium
staining. The proapoptotic effects of the tested steroids were confirmed by fluorescent
microscopy and a caspase-3 activity assay. Treatment-related caspase-9 activation
without a substantial change in caspase-8 activity indicates the induction of the intrinsic
apoptotic pathway. The selected agents directly influence the rate of tubulin assembly
as evidenced by a polymerization assay. Yeast-based reporter gene assay revealed
that the androgenic activity of the novel 19-nortestosterone derivative 3 is by multiple
orders of magnitude weaker than that of the reference agent 1. Based on the behavior
of the examined compounds it can be concluded that a halogen substitution of the
19-nortestosterone scaffold at the 17α position may produce compounds with unique
biological activities. The results of the present study support that structurally modified
steroids with negligible hormonal activity are a promising basis for the research and
development of novel anticancer agents.
Keywords: 19-nortestosterone analogs, antiproliferative action, HeLa Cells, tubulin polymerization, androgenic
activity, cell cycle, caspase
Frontiers in Pharmacology | www.frontiersin.org 1 July 2018 | Volume 9 | Article 825
fphar-09-00825 July 25, 2018 Time: 16:53 # 2
Gyovai et al. Antiproliferative Effects of 19-Nortestosterone Analogs
INTRODUCTION
Cancer is the second leading cause of death globally: in 2015
malignancies were responsible for 8.7 million deaths, and 17.5
million new cancer cases were registered worldwide. Based on
incidence estimates the number of new cases is expected to rise by
about 70% over the next two decades (Fitzmaurice et al., 2017).
Besides numerous preventive strategies and early diagnosis, the
research for and development of innovative anticancer agents is
one of the most important approaches to decrease global cancer
burden.
Steroidal agents used in oncological practice are typically
administered for their endocrine disruptor properties (e.g.,
estrogen antagonists, aromatase inhibitors). Synthetic analogs of
naturally occurring steroids are widely utilized in the treatment of
cancers of the reproductive system (Lin et al., 2010; Sharifi et al.,
2010).
Besides the well-known endocrine disruptors several other
steroids have been reported to exert pronounced anticancer
effects in a hormone-independent manner. 2-Methoxyestradiol,
an endogenous metabolite of estradiol without hormonal activity,
exhibits a potent antiproliferative action against various tumor
cell lines in vitro, and inhibits tumor growth in vivo (Fotsis et al.,
1994). It is also demonstrated to induce programmed cell death in
endothelial cells and suppresses cancer-related angiogenesis (Yue
et al., 1997; LaVallee et al., 2002).
Cardiac glycosides are a group of steroidal compounds
traditionally utilized in the management of congestive heart
failure. Epidemiological studies have revealed that many of them,
including digitoxin, oleandrin, bufalin, and calotropin exert a
potent anticancer effect against different malignancies via the
inhibition of proliferation and apoptosis induction involving
complex cell signal transduction mechanisms (Mijatovic et al.,
2007; Newman et al., 2008).
Steroidal alkaloids are nitrogen containing secondary
metabolites found in many plant families (e.g., Liliaceae,
Solanaceae), and many of them are well characterized as potent
anticancer agents against human malignant cell lines (Koduru
et al., 2007). Solasodine glycosides have been investigated in the
clinical setting against basal cell carcinoma, and a locally applied
cream was found to be effective in a substantial proportion of
patients (Punjabi et al., 2008).
Androstanes and their structural analogs are regarded as
a promising skeleton for the development of steroid-based
anticancer agents. A large body of evidence indicates the
outstanding importance of these compounds and their versatile
antitumor effects. A considerable antiproliferative action of
several sets of innovative androstane analogs have been reported
against a broad variety of cell lines, including prostate, breast,
cervix, ovarium, leukemia, melanoma, colon, and gastric cancers
(Iványi et al., 2012; Ajdukovic et al., 2013, 2015; Acharya
and Bansal, 2014; Cui et al., 2015; Jakimov et al., 2015).
19-Nortestosterone derivatives, e.g., levonorgestrel, desogestrel,
and dienogest, an important division of testosterone-derived
molecules are widely utilized in hormone replacement therapy
(Campagnoli et al., 2005), contraception (Minami et al., 2013;
Royer and Jones, 2014), and treatment of endometriosis
(Minami et al., 2013; Miyashita et al., 2014). Beyond these
well-established clinical applications, several 19-nortestosterone
derivatives have recently been reported as potential anticancer
agents. Mibolerone (7α,17α-dimethyl-19-nortestosterone), a
metabolically stable synthetic member of this class has been
demonstrated to effectively inhibit estrogen-stimulated breast
cancer cell proliferation in vitro (Cops et al., 2008).
Tibolone, a selective regulator of tissue estrogen activity for
postmenopausal women, is also known to induce apoptosis
in breast cancer cells in vitro, and has been demonstrated to
suppress tumor growth in animal models (Franke and Vermes,
2003; Erel et al., 2006). Further, 19-nortestosterones, such
as gestodene and 3-ketodesogestrel exhibit antitumor activity
against several breast cancer cell lines in vitro, as well as
in vivo, in rat model of breast cancer (Kloosterboer et al.,
1994). Additional, 19-nortestosterone derivatives as potential
proliferation inhibitors in brain, prostate, and renal cancer cell
lines have also been described (Mohamed et al., 2015).
Although several analogs truly possess a promising anticancer
effect, their actions are mainly mediated by their hormonal
activity, hindering a wide-scale utilization of these compounds
in cancer therapy.
Since the 17β-hydroxy function of endogen androgens play
a crucial role in the molecule’s interaction with its hormone
receptors, modifications of this group reduce hormonal activity.
The lack of the C-19 methyl group also decreases the hormonal
properties of such analogs substantially (Fragkaki et al., 2009).
In a previous research, we have reported on the synthesis of
a series of 17-substituted 19-nortestosterone derivatives and
demonstrated their antiproliferative properties against human
ovarium, cervix, and breast cancer cell lines. Nandrolone (19-
nortestosterone, 1) was found to exhibit a selective proliferation
inhibitory effect against cervical cancer cells (HeLa) at low
concentrations (Schneider et al., 2016). As an extension of this
previous research a set of novel 19-nortestosterone analogs with
various substituents at position C-17 have been synthesized.
Recent reports about halogen-substituted androstane-derivatives
with an increased in vitro anticancer activity encouraged us
to introduce halogens in order to enhance the antiproliferative
activity (Banday et al., 2010; Iványi et al., 2012). The aims of
our current study were to assess the antiproliferative properties
of these analogs, including tumor selectivity, as well as to
characterize the mechanism of action of the most potent
compound. Since, the endocrine actions of steroid-based drug
candidates are exceptionally relevant, the androgenic potentials
of the compounds were also tested.
MATERIALS AND METHODS
Synthesis and Chemicals
The exact conditions applied for the preparation processes of
the synthesized 19-nortestosterone analogs 2–7 and their detailed
characterization are provided as Supplementary Material. 10 mM
stock solutions of the tested agents were prepared with dimethyl
sulfoxide (DMSO) for all in vitro experiments. The medium
with the highest DMSO concentration (0.3%) did not exert any
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notable effect on cell proliferation. Unless otherwise specified, all
other chemicals and kits were purchased from Sigma-Aldrich Ltd.
(Budapest, Hungary).
Cell Cultures
Gynecological cancer cell lines, including ovarian (A2780),
cervical (HeLa), and breast cancer cell lines (MCF7, T47D,
MDA-MB-231, and MDA-MB-361) were purchased from the
European Collection of Authenticated Cell Cultures (ECACC,
Salisbury, United Kingdom). Additional cervical cell lines (SiHa
and C33A) and a non-cancerous immortalized, mammary gland
epithelial cell line (hTERT-HME1) were purchased from LGC
Standards GmbH (Wesel, Germany). Non-cancerous fibroblast
cells (MRC-5) were also obtained from the ECACC. All cells
were cultured in minimal essential medium supplemented with
10% fetal bovine serum, 1% non-essential amino acids, and
1% antibiotic-antimycotic mixture, in humidified air containing
5% CO2 at 37◦C. Immortalized hTERT-HME1 cells were
maintained in serum-free mammary epithelial cell growth
medium (MEGM) supplemented with insulin, human epidermal
growth factor (hEGF), hydrocortisone, bovine pituitary extract,
and an antibiotic-antimycotic mixture. All the medium and
supplements were purchased from Lonza Group Ltd. (Basel,
Switzerland).
Assessing the Antiproliferative Effect
The antiproliferative properties of the compounds were assessed
by an MTT assay (Mosmann, 1983). Cells were seeded onto
96-well microplates at a density of 10,000 cells/well (MDA-
MB-361 and C33A) or 5,000 cells/well (all other cell lines).
After an overnight incubation, fresh medium containing the test
compounds (at a concentration of 10 or 30 µM) was added.
After incubation for 72 h at 37◦C in humidified air, [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT)
solution (5 mg/mL) was added. Purple formazan crystals were
formed by the living cells during a 4 h contact period, which
were assayed by spectrophotometry after having been dissolved
in 100 µL DMSO. Untreated cells served as control, and cisplatin
(CIS) (Ebewe Pharma GmbH, Unterach, Austria) was used as
a reference compound. When a test agent elicited over 50%
growth inhibition at the 30 µM concentration, the assay was
repeated with a series of dilutions (0.1–30 µM) and IC50 values
were calculated (GraphPad Prism 5.0, GraphPad Software, San
Diego, CA, United States). Two independent measurements
were performed with five parallel wells. To present preliminary
data concerning tumor selectivity of the potent compounds, the
procedure was repeated on MRC-5 fibroblast and hTERT-HME1
immortalized mammary gland epithelial cells under the same
experimental conditions.
Assessing the Cytotoxic Effect
The direct cytotoxic effects of the test agents were determined
by a lactate dehydrogenase (LDH) assay. Cells were seeded
onto 96-well microplates at a density of 5,000 cells/well and
were incubated overnight, after which the medium containing
the test compounds at proper concentrations was added. After
incubation for 24 h, the activity of LDH released by the treated
cells was determined by a commercially available colorimetric
kit according to the manufacturer’s instructions (Hoffmann-La
Roche Ltd., Basel, Switzerland). Untreated cells served as control,
while detergent Triton X-100 and CIS were used as reference
agents.
Flow Cytometric Analysis of Cell Cycle
and Apoptosis
The distribution of cells in different cell cycle phases (subG1,
G1, S and G2/M) was analyzed via the measurement of cellular
DNA content by flow cytometry. HeLa cells were seeded onto 6-
well plates and allowed to stand for an overnight. The cells were
treated with the selected compounds for 24, 48, or 72 h. Then
cells were harvested, washed and fixed in ice cold 70% ethanol
and stored at −20◦C at least for an hour. Next, a DNA staining
solution (containing distilled water, propidium-iodide, Triton-
X100, sodium citrate, and ribonuclease-A) was added to each
sample and stored in the dark at room temperature for an hour.
Stained cells were analyzed by flow cytometry (Partec CyFlow,
Partec GmbH, Munster, Germany) with at least 20,000 cells being
evaluated for each analysis. Data processing was performed using
the ModFit LT 3.3.11 software (Verity Software House, Topsham,
ME, United States).
Morphological Studies Using
Fluorescent Microscopy
Fluorescent double staining was performed in order to
detect apoptosis induction and morphological changes using
fluorescent microscopy. HeLa cells were seeded into a 96-
well plate at the density of 3,000–5,000 cells per well. After
an overnight incubation, the cells were treated with various
concentrations of the test compounds for 24 h. The treated
cells were then incubated with a fluorescent staining solution
(containing Hoechst 33258 and propidium iodide, 500 and
300 µg/mL, respectively) for an hour. After staining, the
cells were analyzed using a fluorescent microscope (Nikon
ECLIPSE 146 TS100, Nikon Instruments Europe, Amstelveen,
Netherlands) equipped with appropriate optical filters. For all
different conditions, at least six fields were recorded with an
attached QCapture CCD camera. This way cells with an intact,
apoptotic or necrotic morphology can be distinguished based
on their different nuclear morphological appearance and distinct
membrane integrity.
Caspase Activity Measurements
In order to detect, whether the test compounds induce
programmed cell death, the activity of caspase-3 was determined
by a colorimetric assay. To elucidate the exact pathway of
apoptosis, activities of caspase-8 and caspase-9 were additionally
determined by colorimetric kits. In all cases approximately 12
million cells were treated with appropriate concentrations of the
compounds for 24 or 72 h. After the treatment, the cells were
scraped and the enzyme activities were determined by means
of colorimetric assays mentioned above. All kits were purchased
from Abnova Corp. (Taipei, Taiwan) and used in accordance with
the instructions of the manufacturer.
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FIGURE 1 | Chemical structures of the synthesized 19-nortestosterone
derivatives. Applied reagents and conditions: (i) Ph3P, aryl acids or alkyl
halogenides, diethyl azodicarboxylate, toluene, 80◦C.
Tubulin Polymerization Assay
In order to determine the direct action of the test compounds on
the microtubular system, an in vitro tubulin polymerization assay
was performed using a commercially available kit (Cytoskeleton
Inc., Denver, CO, United States) in accordance with the
provider’s instructions. The assay reactions were performed
on a pre-warmed (37◦C), UV-transparent 96-well microplate.
Ten microliters of the test solutions were placed on the wells
supplemented with 2 mM MgCl2, 0.5 mM ethylene glycol
tetraacetic acid (EGTA), 1 mM guanosine triphosphate (GTP)
and 10.2% glycerol. Ten microliters of general tubulin buffer was
used as untreated control, and paclitaxel (PAC) served as the
reference compound. The polymerization reaction was initiated
by adding 100 µL of 3.0 mg/mL tubulin in 80 mM PIPES, pH
6.9, to each sample. Absorbance of the samples was measured
per minute, at 340 nm, using a 60-min kinetic measurement
protocol. Each sample was prepared in two parallels. To
characterize the process, polymerization curves were fitted to the
measured data. The highest difference between the absorbances
measured at two consecutive time points was regarded as
Vmax (1absorbance/min) for the tested compound. A clinically
applied reference agent, PAC was used at a relatively high
concentration (10 µM) as recommended by the manufacturer.
This concentration is approximately 1,000-fold higher than the
IC50 value of PAC on HeLa cells (Jordan et al., 1996). Since
similarly high concentrations of the tested compounds were
not possible to be applied because of the limited solubility of
the substances in the recommended buffer, we used the highest
concentrations reflecting the differences in the efficacies of the
tested compounds.
Assessing Hormonal Effect
An endocrine bioassay kit (Xenometrix AG, Allschwil,
Switzerland) was used to test for a potential residual androgenic
TABLE 1 | Antiproliferative effects of the synthesized compounds (1–7) on human cell lines.
Comp. Conc. (µM) Growth inhibition (%) ± SEM [calculated IC50 value (µM)]a
HeLa SiHa C33A A2780 MCF-7 MDA-MB-231 MDA-MB-361 T47D MRC-5 hTERT-HME1
1b 10 99.5 ± 0.2 –c – – – – – – 5.4 ± 1.2 16.9 ± 1.2
30 99.5 ± 0.3 20.7 ± 2.6 25.2 ± 1.7 – – 21.4 ± 1.2 – – 11.3 ± 0.5 37.1 + 1.0
[0.65]
2b 10 28.1 ± 4.0 – – – – – – – n.d.d n.d.
30 37.9 ± 3.4 – – – 27.7 ± 3.7 – – –
3 10 95.9 ± 0.3 – – – – – – – 4.3 ± 3.7 76.2 ± 0.5
30 95.1 ± 0.5 26.0 ± 2.3 61.7 ± 1.7 32.7 ± 1.0 36.9 ± 2.0 – 21.8 ± 2.5 – 8.0 ± 2.3 99.9 ± 0.1
[1.21] [4.63]
4 10 94.4 ± 0.7 – – – – – – – 11.9 ± 2.3 n.d.
30 94.1 ± 0.5 – – 54.4 ± 1.6 – – – – 20.4 ± 2.1
[1.69]
5 10 95.2 ± 0.4 – – 27.7 ± 1.3 – – – – 13.1 ± 1.9 n.d.
30 95.8 ± 0.2 – – 61.6 ± 1.8 – – – – 13.8 ± 2.0
[1.49]
6 10 32.0 ± 2.9 – – – – – – – n.d. n.d.
30 26.5 ± 2.3 – – 31.9 ± 2.6 35.9 ± 1.4 – – 47.2 ± 2.6
7 10 26.6 ± 1.8 – – 49.2 ± 0.9 25.9 ± 3.1 – – – n.d. n.d.
30 21.5 ± 1.9 – – 58.1 ± 2.0 37.7 ± 3.4 – 22.0 ± 1.6 –
CISe 10 42.6 ± 2.3 88.6 ± 0.5 83.8 ± 0.8 83.6 ± 1.2 66.9 ± 1.8 – 67.5 ± 1.0 51.0 ± 2.0 60.3 ± 3.3 97.7 ± 0.3
30 99.9 ± 0.3 90.2 ± 1.8 93.9 ± 0.6 95.0 ± 0.3 96.8 ± 0.4 71.5 ± 1.2 87.8 ± 1.1 55.0 ± 1.5 61.9 ± 1.0 99.1 ± 0.3
12.43 7.84 1.77 1.30 5.78 19.13 3.74 9.78 6.19 [2.45]
a IC50 values were calculated when the growth inhibition value for a compound exceeded 75% at a concentration of 30 µM. See Supplementary Figure S1 for representative
concentration-response curves. bData previously reported (Schneider et al., 2016). c Inhibition values less than 20% are not presented. dn.d., not determined. eReference
agent cisplatin.
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activity of the selected agents. Genetically modified yeast cells
(Saccharomyces cerevisiae) containing the human androgenic
receptor gene integrated into a yeast chromosome, as well
as an expression plasmid with the sequences of both the
androgen responsive element and a lacZ reporter gene were
cultured in humidified air at 31◦C with agitation for 2 days. The
appropriate concentrations of the test compounds and a CPRG
substrate solution (chlorophenol red-β-D-galactopyranoside) for
β-galactosidase were added into a 96-well microplate according
to the instructions of the manufacturer. Androgen agonistic and
antagonistic properties of the test compounds were determined
by a colorimetric assay. For the antagonistic measurements the
medium was supplemented with 5α-dihydrotestosterone (DHT).
Once the reporter gene is expressed, β-galactosidase is secreted
into the medium, and converts the yellow CPRG substrate into
a red product, which can be quantified at 570 nm. Quantities of
this red product correlate with the liberation of β-galactosidase,
which is increased when an agonistic effect is present, while it is
decreased when the test compound exerts an antagonistic effect.
For the agonistic and antagonistic assays, nandrolone (1) and
flutamide were used as reference agents, respectively.
Statistical Analysis
In all experiments, the statistical evaluation of the results
was performed by one-way analysis of variance followed by
the Dunnett posttest, using the GraphPad Prism 5 software
(GraphPad Software; San Diego, CA, United States). Mean values
and the SEM were calculated in all cases.
RESULTS
Synthetic Studies
The Mitsunobu reaction is widely employed for the inversion
of stereogenic centers of secondary alcohols including steroid
alcohols. The reaction allows the conversion of alcohols with
alkyl or aryl carboxylic acids in the presence of diethyl
azodicarboxylate and triphenylphosphine (Ph3P). The result
is an alkyl- or aryl carboxylic ester of the alcohol with
inverted configuration (Mitsunobu, 1981). Here, we describe
the Mitsunobu reaction for 19-nortestosterone (1) utilizing
2,4-, or 3,5-dinitrobenzoic acid in the presence of diethyl
azodicarboxylate and Ph3P in toluene at 80◦C leading to
the corresponding 17α-19-nortestosterone-17-yl 2′,4′- or 3′,5′-
dinitrobenzoate (6 or 7, respectively; Figure 1). Reacting
compound 1 with isopropyl halides under the same conditions
produces the corresponding 17α-chloro-, bromo-, and iodo-19-
nortestosterone (3–5, respectively). Hydrolyzing compounds 6
or 7 in methanol, in the presence of NaOCH3 yields 17α-19-
nortestosterone (2).
Antiproliferative Properties of
19-Nortestosterone Derivatives
The antiproliferative activities of the test compounds were
determined by MTT assay on a panel of adherent gynecological
cancer cell lines (Table 1). Nandrolone (1) as reported previously,
FIGURE 2 | Cytotoxic effects of compounds 1, 3 and cisplatin on HeLa cells
after 24 h treatment. The effect of Triton X-100 (T) was considered 100%.
Results are mean values ± SEM of the data from two separate
measurements, n = 4. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 compared to
untreated control (C).
exerted a considerable antiproliferative effect against HeLa cells.
Compounds 2, 6, and 7 exerted no remarkable antiproliferative
action against the gynecological cancer cell lines. 17α-Halogen
derivatives (3–5) exerted a pronounced antiproliferative effect
against HeLa cells, while they did not elicit any notable
influence on the remaining cell lines including fibroblasts. These
derivatives had lower IC50 values on HeLa cells than that of the
reference agent CIS. Compound 3 proved to be the most potent
antiproliferative agent, characterized by an effect size comparable
to that of 1. Cancer selectivity of the potent compounds
was determined by the same method using human fibroblasts
(MRC-5) and non-cancerous immortalized, mammary gland
derived epithelial (hTERT-HME1) cells. None of the test agents
exhibited a considerable growth inhibitory effect against intact
fibroblasts up to a concentration of 30 µM. Compound 1 had
no pronounced action on immortalized epithelial cells, while
compound 3 inhibited the growth of these cells with an IC50 value
approximately four times higher than that obtained on HeLa
cells. Compound 3 exerted the most explicit tumor selectivity,
showing a substantially weaker effect on non-cancerous cells
than CIS. Due to their potent and selective antiproliferative
actions, compound 3 and nandrolone (1) were selected for
further investigations to characterize their mechanism of action
and assess their hormonal effect.
Cytotoxic Activity
Cytotoxic properties of the selected compounds were ascertained
by measuring LDH activity resulting from cell membrane
damage. Each molecule exerted a concentration-dependent
increase of LDH activity compared to the untreated control
after 24 h treatment (Figure 2). Compound 1 elicited a
substantial LDH release at a concentration of 1.5 µM. The
effect of compound 3 proved to be significant when applied at
concentrations above its IC50 values (3.0 or 5.0 µM). None of the
test agents induced an LDH activity comparable to the maximum
LDH release triggered by detergent Triton X-100.
Cell Cycle Analysis
Alterations in cell cycle and apoptotic fragmentations were
determined by flow cytometry after treatment with the test
compounds for 24 and 48 h. Since 1 elicited no change in
the subG1 population at these time points this agent was
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FIGURE 3 | Effects of compounds 1 and 3 on cell cycle phase distribution of HeLa cells determined by flow cytometry after incubation for 24, 48, or 72 h. Results
are mean values ± SEM of the data from two independent measurements, n = 6. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 compared to untreated control.
re-tested after 72 h incubation. Treatment with 1 for 24 h
resulted in a concentration-dependent and significant decrease
in the G1 and a moderate but significant increase in the G2/M
phase cell population (Figure 3). After 48 h of exposure these
changes became more pronounced, and completed with the
elevated ratio of the S phase cell population in the presence of
1.5 µM of 1. A longer incubation time (72 h) with 1 elicited
a substantial disturbance in the cell phase distribution and
a concentration-dependent accumulation of hypodiploid cells
indicating apoptotic nuclear fragmentation. Compound 3 did
not have any remarkable effect on cell cycle after 24 h exposure,
while a longer incubation time (48 h) resulted in a substantially
elevated increase of the subG1 population at the expense of G1
cells.
Morphological Changes
To characterize the morphological features of the apoptosis
induced by compounds 1 and 3 HeLa cells were examined
by fluorescent microscopy after 24 h treatment with three
different concentrations (1.0, 3.0, or 5.0 µM) of the test
compounds. For the quantitative analysis, cells with intact,
apoptotic and necrotic morphological features were labeled,
and the ratios of different morphologies were calculated.
Treatments with 1 and 3 resulted in a substantial and
concentration-dependent increase in both the apoptotic and
necrotic cell populations, at the expense of the intact population
(Figure 4).
Induction of Apoptotic Enzymes
Based on the above results, changes of the activities of
caspase-3, caspase-8, and caspase-9 were determined using
a colorimetric assay. After treatment with 1 for 72 h, the
activity of executive caspase-3 increased significantly and in a
concentration-dependent manner (Figure 5). Under the same
experimental conditions 1 also activated the initiator caspases,
although the induction of caspase-8 was less pronounced.
Compound 3 enhanced caspase-3 activity at 5.0 µM even after
a shorter incubation period (24 h). Caspase-9 activity was also
significantly elevated, while there was no change in the function
of caspase-8.
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FIGURE 4 | Qualitative evaluation of fluorescent double staining of HeLa cells
after 24 h treatment with compounds 1 or 3. ∗p < 0.05 and ∗∗∗p < 0.001
compared to untreated control (C). See Supplementary Figure S2 for
representative pictures.
Tubulin Polymerization
The direct effect of the test compounds on microtubule formation
was determined by a specific photometric assay in a cell-
free system. The tested concentrations of the compounds were
chosen based on their calculated IC50 values according to the
recommendation of the manufacturer. Both compounds 1 and 3
induced a significant acceleration of tubulin polymerization
compared to untreated control samples (Figure 6). Calculated
values of maximal rate of tubulin polymerization (Vmax) were
elevated compared to control, although none of theseVmax values
were comparable to that of the reference agent PAC.
Hormonal Effect
Since residual hormonal activity of a potential sterane lead
compound is a crucial aspect of further drug development,
the androgenic properties of the most promising agents were
investigated by a yeast-based reporter assay. As 1 is a well-
characterized androgen, it was used as a reference agent (Bergink
et al., 1985). According to our results 3 exerts a substantially
lower hormonal activity, with no relevant action unless applied
in extremely high concentrations (Figure 7). Calculated EC50
values of 1 and 3 differed by approximately 2 orders of magnitude
(3.43 × 10−8 and 3.80 × 10−6 M, respectively). Compound 3
exhibited no antagonistic activity in the assay system (data not
shown).
DISCUSSION
Various biological effects of compounds with an androstane
skeleton mostly stem from their endocrine disruptor properties,
thus the medical use of androgens is mainly limited to androgen
replacement and androgen deprivation therapies, including
the management of some hormone dependent malignancies
(Wadosky and Koochekpour, 2016). Beyond their approved
medical applications, numerous androgenic anabolic steroids
are utilized illegally to enhance physical performance, a risky
use often accompanied by serious adverse effects. Recently,
numerous androstanes with anticancer potential have been
described, and the importance of androstane compounds and
their derivatives in the research and development of steroid-
based anticancer agents for hormone-independent malignancies
is continuously increasing (Frank and Schneider, 2013; Wadosky
and Koochekpour, 2016). Although several 19-nortestosterone
derivatives have been identified as potent anticancer agents
(e.g., mibolerone, tibolone, gestodene), most of them have
pronounced hormonal properties involved in their therapeutic
action, as well as in their undesired adverse effects (Saito et al.,
2016). In a previous research, we investigated a set of newly
synthesized 19-nortestosterone analogs, and reported that some
of them exhibited a moderate antiproliferative activity. That
study of our research group revealed that the widely known 19-
nortestosterone analog 1 (nandrolone) has a potent and selective
antiproliferative effect against cervical carcinoma cells positive
for type 18 of human papilloma virus (HPV-18) (Schneider et al.,
2016).
The aim of our present study was to synthesize and investigate
a set of novel 19-nortestosterone derivatives with improved
antiproliferative properties and limited hormonal activities.
Three of the novel compounds (3–5) were found to exhibit a
pronounced antiproliferative effect against HeLa cells (calculated
IC50 values: 1.21–1.69 µM), while exerting a negligible or
lower impact on other cell lines including intact fibroblasts
(MRC-5) and the immortalized mammary gland epithelial cell
line (hTERT-HME1). In contrast, dinitrobenzoates (6 and 7)
appeared to be ineffective in terms of growth inhibition of cancer
cells. The most potent compound, 3 was further investigated
to describe its possible mechanism of action. A well-known
androgen, 1 a with similar antiproliferative capacity was utilized
as a steroidal reference agent.
The antiproliferative property of a compound is typically
reflected by a disturbance induced in cell cycle distribution.
These changes in cell cycle phases inform about the probable
mechanism of the antiproliferative action. Both 1 and 3 caused
a cell cycle disturbance characterized by the accumulation of
hypodiploid (subG1) cells at the expense of the G1 population.
The increase of hypodiploid cell populations can be
regarded as an evidence for proapoptotic properties of the
test compounds. Alterations in cell cycle during physiological
conditions usually lead to induction of programmed cell death.
Activation of the apoptotic machinery, selectively in cancer
cells without a substantial necrotizing effect is one of the
most desirable characteristics of a promising anticancer agent
(Tolomeo and Simoni, 2002). Some steroidal compounds with
anticancer activity (e.g., 2-methoxyestradiol, D-homoestrone, a
D-secoestrone-triazole analog) have been described as efficacious
inducers of programmed cell death in cancer cells (Li et al.,
2004; Minorics et al., 2015; Bózsity et al., 2017). Therefore, the
demonstration of apoptosis induction was a basic feature of our
study. We utilized fluorescent microscopy and observed the
characteristic features of apoptosis elicited by the test agents in a
concentration-dependent manner.
Caspase enzymes are crucial implementers of the apoptotic
program executed by downstream effector caspases such as
caspase-3. Caspase-9 is the major enzyme involved in the
initiation of the intrinsic apoptotic pathway, while caspase-
8 plays an essential role in the extrinsic pathway of the
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FIGURE 5 | Activation of caspase-3, caspase-8, and caspase-9 enzymes in HeLa cells after incubation with compounds 1 and 3 for 72 or 24 h, respectively. Results
are mean values ± SEM of the data from two independent measurements, n = 6. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 compared to untreated control.
apoptotic process (Hajra and Liu, 2004). Treatments with
the test compounds resulted in a significant elevation in the
activity of caspase-3, reflecting the activation of apoptotic
cell death. Both agents elicited a considerable increase in
activity of caspase-9 at both concentrations tested (1 and
5 µM) without expected concentration-dependency. The exact
reason for this is not elucidated, but based on the results
of our fluorescent microscopy analysis, necrotic cell death
induced by the higher concentration could be a plausible
explanation. Based on these findings activation of the intrinsic
apoptotic pathway is hypothesized. Although, the activity of
caspase-8 was slightly but significantly increased by 1 at a
concentration of 1 µM, this limited change seems to be
inefficient to indicate a dominant role of the extrinsic apoptotic
pathway.
Previous studies revealed that some proapoptotic steroidal
compounds induced a pronounced cell cycle arrest via a
direct influence on tubulin polymerization during mitosis. The
inhibitory effect of 2-methoxyestradiol on microtubule formation
resulting from its interaction with the colchicine-binding site of
β-tubulin has also been reported (Peyrat et al., 2012). Thus, a
possible direct influence of 1 and 3 on the polymerization of
tubulin heterodimers in a cell-free system was also investigated.
Both of our test agents elicited a concentration-dependent
acceleration of the polymerization reaction as reflected by
significantly increased Vmax values. This molecular behavior
indicates a possible PAC-like microtubule stabilizing effect of the
test compounds which may contribute to cell cycle arrest and lead
to the induction of the apoptotic machinery.
The possible androgenic activity of a novel steroid-based
agent may implicate a source of potential adverse reactions
limiting its therapeutic value. Receptor binding properties of
1 and 5α-dihydrotestosterone are indistinguishable by a radio
ligand assay using androgen receptors prepared from rat prostate
and MCF-t cells (Bergink et al., 1985). Therefore, 1 can be
utilized as a reference agent when novel compounds with
possible androgenic properties are characterized. Compound 3
was detected to possess a substantially lower androgenic activity
compared to 1.
Moreover, 3 had no androgen antagonistic properties when
tested in the presence 5α-dihydrotestosterone. This hormonal
neutrality of 3 could be explained by the α-position of chlorine
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FIGURE 6 | Direct effects of compounds 1 and 3 on tubulin polymerization. Kinetic curves characterizing tubulin polymerization in the presence of 1, 3 or paclitaxel
(PAC) were recorded after 58 min kinetic measurements (Left). Direct effects of the test agents on the maximal rate of polymerization were evaluated (Right). Results
are mean values ± SEM of the data from two independent measurements, n = 4. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 compared to untreated control sample.
on the ring D of the skeleton. The substituent at position 17
determines receptor binding, and only the β configuration is
favored. Consequently, 17α-testosterone has virtually no affinity
for the receptor (Fragkaki et al., 2009).
Although mediated by the same nuclear receptor,
androgenic and anabolic actions of a ligand can be partially
dissociated depending on the tissue expression of crucial
metabolic enzymes including 5α-reductase. While the
androgenic action may be disadvantageous and may limit
the development of a drug candidate, an anabolic or
“myotropic” property could theoretically be advantageous
when a chronic or devastating disease is treated (Tóth and Zakár,
1982).
Beside the well-characterized action of androgens mediated
via androgen response elements within the DNA, the presented
19-nortestosterone analogs may also interact with membrane-
associated androgen receptors (Kampa et al., 2006). This latter
action could be of special importance since the stimulation
of these receptors elicits an increase in the intracellular free
zinc concentration accompanied by induction of apoptosis
in cancer cell (Thomas et al., 2014).Two further membrane-
bound proteins have been recently reported as potential
non-genomic receptors for androgens and related steroids.
One of them is the putative G-protein coupled receptor
GPRC6A, an amino acid, calcium, and osteocalcin sensing
receptor. The interaction of this receptor with testosterone
is reported to result in increased phosphorylation of
extracellular signal-regulated kinases in human embryonic
kidney cells expressing the GPRC6A protein (Pi et al.,
2010).
FIGURE 7 | Effects of compounds 1 and 3 in the yeast-based androgenic
reporter assay. Results are mean values ± SEM of the data from two
independent measurements, n = 4.
Oxoeicosanoid receptor 1 (OXER1) is a membrane receptor
for the arachidonic acid metabolite 5-oxoeicosatetraenoic acid (5-
oxoETE) and serves as a binding site for testosterone in prostate
cancer cells. The steroid testosterone is reported to antagonize
the action of the natural agonist 5-oxoETE on the intracellular
cAMP production, and the interaction between testosterone and
OXER1 was confirmed by an in silico molecular docking study as
well (Kalyvianaki et al., 2017).
Since apoptosis and cell growth are indirectly involved in
the signal mechanism of these non-genomic receptors, an action
mediated by membrane-bound steroid receptors may contribute
to the overall effects of the presented compounds.
In summary, our present results demonstrated that three of a
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set of newly synthesized 19-nortestosterone exhibit a pronounced
antiproliferative activity against cervical carcinoma cells with
lower influence on fibroblasts and a modest action on non-
cancerous immortalized epithelial cells. The most potent
agent 3 is characterized by a moderate cytotoxic effect,
elicits cell cycle disturbance and induces the mitochondrial
pathway of apoptosis. As a possible molecular mechanism
of these actions, a PAC-like microtubule-stabilizing property
is suggested based on its direct effect on the microtubular
system.
Based on our present findings, the 19-nortestosterone
backbone with a 17α-halogen substitution provides an
excellent skeleton for designing novel antiproliferative steroidal
compounds with negligible androgenic activity.
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